“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer”
April – June
Financial summary…
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed…
In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May…
”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA,…
The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has…
The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options.…
Today on 1 December 2023, Medivir AB (publ) (the “Company”) held an extraordinary general meeting in Stockholm, whereby the resolution…
The shareholders in Medivir AB (publ) reg. no. 556238-4361 (the “Company”) are hereby convened to the extraordinary general meeting, which…
“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Continued strong momentum and promising signs of patient benefit in the combination study with…
Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima[®]
April – June
Financial summary…
· Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment
…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares…
Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 4 May…
The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2023.
Die folgenden Instrumente in Boerse Frankfurt haben…
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
SE0000273294 Medivir AB 15.05.2023 SE0020181014 Medivir AB 16.05.2023 Tausch 1:1
US9840155033 Xenetic Biosciences Inc. 15.05.2023 US9840156023 Xenetic Biosciences Inc. 16.05.2023 Tausch 10:1
GRS314003005 Mig Holdings S.A. 15.05.2023 GRS314003013 Mig Holdings S.A. 16.05.2023 Tausch 1:1
GB00BN0SMB92 Capricorn Energy PLC 15.05.2023 GB00BQ98V038 Capricorn Energy…
STOCKHOLM, May 4, 2023 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The…
Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by…
HUDDINGE, Sweden, April 27, 2023 /PRNewswire/ -- "Thanks to the strong interest from clinicians and patients, we were able to…
“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, April 4, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the Annual Report for 2022 now…
Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at…
STOCKHOLM, March 31, 2023 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in…
The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, Feb. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
HUDDINGE, Sweden, Feb. 15, 2023 /PRNewswire/ -- Continued strong recruitment in the dose escalation part of the fostrox study. October…
Continued strong recruitment in the dose escalation part of the fostrox study.
October – December
Financial summary for the quarter
·…
STOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…
STOCKHOLM, Jan. 11, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading…
Stockholm, Sweden— Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been…
STOCKHOLM, Dec. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments…